Details for New Drug Application (NDA): 012329
✉ Email this page to a colleague
NDA 012329 describes ISMELIN, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the ISMELIN profile page.
The generic ingredient in ISMELIN is guanethidine monosulfate. There are two drug master file entries for this compound. Additional details are available on the guanethidine monosulfate profile page.
The generic ingredient in ISMELIN is guanethidine monosulfate. There are two drug master file entries for this compound. Additional details are available on the guanethidine monosulfate profile page.
Summary for 012329
| Tradename: | ISMELIN |
| Applicant: | Novartis |
| Ingredient: | guanethidine monosulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 012329
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 10MG SULFATE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 25MG SULFATE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
